YU13902A - Mesoprogestins (progesterone receptor modulators) as a component of female contraceptives - Google Patents
Mesoprogestins (progesterone receptor modulators) as a component of female contraceptivesInfo
- Publication number
- YU13902A YU13902A YU13902A YUP13902A YU13902A YU 13902 A YU13902 A YU 13902A YU 13902 A YU13902 A YU 13902A YU P13902 A YUP13902 A YU P13902A YU 13902 A YU13902 A YU 13902A
- Authority
- YU
- Yugoslavia
- Prior art keywords
- mesoprogestins
- female
- progesterone receptor
- component
- contraception
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present invention relates to the use of mesoprogestins for the production of a pharmaceutical for female contraception, to a pharmaceutical preparation for female contraception and to a method of female contraception administering effective amounts of a mesoprogestin in a female desiring contraception. Optionally the mesoprogestin can be used in combination with an estrogen. Mesoprogestins are defined as compounds possessing both agonistic and antagonistic activities at the progesterone receptor (PR) in vivo. They stabilize the function of PR at an intermediate level of agonistic and antagonistic. Corresponding functional states cannot be achieved with progestins or antiprogestins. J867, J912, J956 and J1042 are the mesoprogestins preferred according to the invention.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US38613399A | 1999-08-31 | 1999-08-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
YU13902A true YU13902A (en) | 2006-01-16 |
Family
ID=23524305
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
YU13902A YU13902A (en) | 1999-08-31 | 2000-08-31 | Mesoprogestins (progesterone receptor modulators) as a component of female contraceptives |
Country Status (28)
Country | Link |
---|---|
EP (1) | EP1605949A2 (en) |
JP (1) | JP2003511399A (en) |
KR (1) | KR20020038745A (en) |
CN (1) | CN1384748A (en) |
AR (1) | AR025455A1 (en) |
AU (1) | AU781835B2 (en) |
BG (1) | BG106441A (en) |
BR (1) | BR0013711A (en) |
CA (1) | CA2383650A1 (en) |
CO (1) | CO5190694A1 (en) |
CZ (1) | CZ2002707A3 (en) |
EA (1) | EA006805B1 (en) |
EE (1) | EE200200103A (en) |
HR (1) | HRP20020265A2 (en) |
HU (1) | HUP0202515A3 (en) |
IL (1) | IL148415A0 (en) |
LT (1) | LT5001B (en) |
LV (1) | LV12940B (en) |
MX (1) | MXPA02002186A (en) |
NO (1) | NO20020998L (en) |
NZ (1) | NZ517470A (en) |
PE (1) | PE20010579A1 (en) |
PL (1) | PL353994A1 (en) |
SI (1) | SI20853A (en) |
SK (1) | SK2982002A3 (en) |
UA (1) | UA77150C2 (en) |
WO (1) | WO2001026603A2 (en) |
YU (1) | YU13902A (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK1525215T3 (en) * | 2002-08-02 | 2007-01-15 | Schering Ag | Modulators for the progesterone receptor with elevated anti-gonadotropic activity for women's fertility control and hormone replacement therapy |
DE10236405A1 (en) | 2002-08-02 | 2004-02-19 | Schering Ag | New 4-(3-oxo-estra-4,9-dien-11 beta-yl)-benzaldehyde oximes, are progesterone receptor modulators useful in female contraception, hormone replacement therapy and treatment of gynecological disorders |
US7772219B2 (en) * | 2003-05-02 | 2010-08-10 | Teva Women's Health, Inc. | Methods of hormonal treatment utilizing extended cycle contraceptive regimens |
US20050215535A1 (en) * | 2004-03-24 | 2005-09-29 | Kristof Chwalisz | Sequential SPRM/progestin treatment |
BRPI0512991A (en) * | 2004-07-07 | 2008-04-22 | Wyeth Corp | use of a progestin, pharmaceutically useful kit adapted for daily oral administration, and method of contraception in a female of childbirth |
DE102005050729A1 (en) * | 2005-10-19 | 2007-04-26 | Schering Ag | Method of preventive on-demand hormonal contraception |
NZ615430A (en) * | 2009-04-14 | 2014-06-27 | Laboratoire Hra-Pharma | Method for on-demand contraception |
CN110548034A (en) * | 2019-07-12 | 2019-12-10 | 广州莎蔓生物科技有限公司 | Pregnancy-blocking medicine |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2054271A (en) | 1932-05-17 | 1936-09-15 | Schering Kahlbaum Ag | Production of crystallized hormone esters |
DE699310C (en) | 1936-11-20 | 1940-11-27 | Chemische Ind Ges | Process for the preparation of compounds of the estradiol type which are esterified in the 3-position |
US2225419A (en) | 1937-03-01 | 1940-12-17 | Schering Corp | Process for the conversion of 17-cisalcohols of the cyclopentanopolyhydrophenanthrene series into the corresponding 17-trans-alcohols |
US2611773A (en) | 1951-08-21 | 1952-09-23 | Upjohn Co | Estradiol 17-cyclopenetanepropionate |
US2990414A (en) | 1957-03-26 | 1961-06-27 | Syntex Sa | 17-undecenoate of estradiol |
DE3337450A1 (en) | 1983-10-12 | 1985-04-25 | Schering AG, 1000 Berlin und 4709 Bergkamen | PROSTAGLANDINE AND ANTIGESTAGE FOR PREGNANCY ABORT |
HU214598B (en) * | 1987-09-24 | 1998-04-28 | Jencap Research Ltd | Process for producing contraceptive compositions containing estragen and progestin and applicable for hormonal therapy |
US5439913A (en) | 1992-05-12 | 1995-08-08 | Schering Aktiengesellschaft | Contraception method using competitive progesterone antagonists and novel compounds useful therein |
US5516769A (en) | 1993-02-19 | 1996-05-14 | The Medical College Of Hampton Roads | Method of inhibiting fertilization |
DE4332284C2 (en) * | 1993-09-20 | 1997-05-28 | Jenapharm Gmbh | 11-Benzaldoxime-17beta-methoxy-17alpha-methoxymethyl-estradiene derivatives, process for their preparation and medicaments containing these compounds |
DE4332283A1 (en) * | 1993-09-20 | 1995-04-13 | Jenapharm Gmbh | Novel 11-benzaldoximestradiene derivatives, processes for their preparation and medicaments containing these compounds |
DE4429397C2 (en) | 1994-08-09 | 2003-11-20 | Jenapharm Gmbh | Estra-1,3,5 (10) -triene derivatives, processes for their preparation and pharmaceutical compositions containing these compounds |
DE4447715C2 (en) | 1994-08-09 | 1998-02-05 | Jenapharm Gmbh | Oestrogen compsn contg. 3-sulphamoyl:oxy-oestratriene cpd. |
ZA959008B (en) * | 1994-10-24 | 1996-09-16 | Schering Ag | Competitive progesterone antagonists for demand-oriented female birth control |
US6040340A (en) * | 1996-05-07 | 2000-03-21 | Schering Aktiengesellschaft | Implantation rates after in vitro fertilization, treatment of infertility and early pregnancy loss with a nitric oxide donor alone or in combination with progesterone, and a method for contraception with nitric oxide inhibitors |
JP2000514785A (en) * | 1996-06-25 | 2000-11-07 | アクゾ・ノベル・エヌ・ベー | Progestogen-anti-progestogen prescription |
WO1998005679A2 (en) * | 1996-08-05 | 1998-02-12 | Duke University | Mixed agonists of the progesterone receptor and assays therefor |
DE19809845A1 (en) * | 1998-03-03 | 1999-09-09 | Jenapharm Gmbh | S-substituted 11beta-benzaldoxime-estra-4,9-diene-carbonic acid thiol esters, processes for their preparation and pharmaceutical preparations containing these compounds |
EP1175422A2 (en) * | 1999-05-04 | 2002-01-30 | Ligand Pharmaceuticals Incorporated | Tetracyclic progesterone receptor modulator compounds and methods |
-
2000
- 2000-08-31 CN CN00812308A patent/CN1384748A/en active Pending
- 2000-08-31 IL IL14841500A patent/IL148415A0/en unknown
- 2000-08-31 HU HU0202515A patent/HUP0202515A3/en unknown
- 2000-08-31 YU YU13902A patent/YU13902A/en unknown
- 2000-08-31 AR ARP000104536A patent/AR025455A1/en unknown
- 2000-08-31 AU AU32150/01A patent/AU781835B2/en not_active Ceased
- 2000-08-31 CZ CZ2002707A patent/CZ2002707A3/en unknown
- 2000-08-31 JP JP2001529395A patent/JP2003511399A/en active Pending
- 2000-08-31 EP EP00991299A patent/EP1605949A2/en not_active Withdrawn
- 2000-08-31 NZ NZ517470A patent/NZ517470A/en unknown
- 2000-08-31 KR KR1020027002785A patent/KR20020038745A/en not_active Application Discontinuation
- 2000-08-31 BR BR0013711-1A patent/BR0013711A/en not_active IP Right Cessation
- 2000-08-31 WO PCT/IB2000/002053 patent/WO2001026603A2/en not_active Application Discontinuation
- 2000-08-31 EE EEP200200103A patent/EE200200103A/en unknown
- 2000-08-31 EA EA200200284A patent/EA006805B1/en not_active IP Right Cessation
- 2000-08-31 SI SI200020043A patent/SI20853A/en not_active IP Right Cessation
- 2000-08-31 SK SK298-2002A patent/SK2982002A3/en unknown
- 2000-08-31 PL PL00353994A patent/PL353994A1/en not_active Application Discontinuation
- 2000-08-31 PE PE2000000894A patent/PE20010579A1/en not_active Application Discontinuation
- 2000-08-31 CA CA002383650A patent/CA2383650A1/en not_active Abandoned
- 2000-08-31 UA UA2002032429A patent/UA77150C2/en unknown
- 2000-08-31 MX MXPA02002186A patent/MXPA02002186A/en not_active Application Discontinuation
- 2000-08-31 CO CO00065517A patent/CO5190694A1/en not_active Application Discontinuation
-
2002
- 2002-02-26 BG BG06441A patent/BG106441A/en unknown
- 2002-02-28 NO NO20020998A patent/NO20020998L/en not_active Application Discontinuation
- 2002-03-26 LT LT2002035A patent/LT5001B/en not_active IP Right Cessation
- 2002-03-28 HR HR20020265A patent/HRP20020265A2/en not_active Application Discontinuation
- 2002-03-28 LV LVP-02-52A patent/LV12940B/en unknown
Also Published As
Publication number | Publication date |
---|---|
PL353994A1 (en) | 2003-12-15 |
HUP0202515A2 (en) | 2002-12-28 |
EP1605949A2 (en) | 2005-12-21 |
SI20853A (en) | 2002-10-31 |
MXPA02002186A (en) | 2002-09-02 |
WO2001026603A2 (en) | 2001-04-19 |
BR0013711A (en) | 2002-05-07 |
SK2982002A3 (en) | 2002-07-02 |
CO5190694A1 (en) | 2002-08-29 |
HUP0202515A3 (en) | 2004-06-28 |
KR20020038745A (en) | 2002-05-23 |
PE20010579A1 (en) | 2001-06-04 |
NO20020998L (en) | 2002-03-14 |
NZ517470A (en) | 2004-03-26 |
LT2002035A (en) | 2002-10-25 |
EA200200284A1 (en) | 2002-10-31 |
LT5001B (en) | 2003-03-25 |
JP2003511399A (en) | 2003-03-25 |
EA006805B1 (en) | 2006-04-28 |
CZ2002707A3 (en) | 2002-11-13 |
UA77150C2 (en) | 2006-11-15 |
HRP20020265A2 (en) | 2004-02-29 |
AR025455A1 (en) | 2002-11-27 |
EE200200103A (en) | 2003-04-15 |
CA2383650A1 (en) | 2001-04-19 |
NO20020998D0 (en) | 2002-02-28 |
AU781835B2 (en) | 2005-06-16 |
AU3215001A (en) | 2001-04-23 |
WO2001026603A3 (en) | 2002-01-17 |
BG106441A (en) | 2002-09-30 |
LV12940B (en) | 2003-06-20 |
IL148415A0 (en) | 2002-09-12 |
CN1384748A (en) | 2002-12-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TW200607798A (en) | Progesterone receptor modulators comprising pyrrole-oxindole derivatives and uses thereof | |
TW200605882A (en) | Progesterone receptor modulators comprising pyrrole-oxindole derivatives and uses thereof | |
BG101553A (en) | Progesterone antagonist and antiestrogenous active compounds of general application for female contraceptives | |
WO2002047693A3 (en) | Steroid hormone products comprising a stabilizing agent in non-crystalline form | |
WO2000066590A3 (en) | Tetracyclic progesterone receptor modulator compounds and methods | |
CA2188907A1 (en) | Combination compound for contraception based on natural estrogen | |
WO2004110408A3 (en) | Process for the manufacture of stable shaped particles consisting of estradiol and cholesterol | |
HUP0104037A3 (en) | Drug delivery device, especially for the delivery of progestins and estrogens | |
UA37259C2 (en) | Active substance for pharmaceutical compositions intended for treatment of dysfunctional metrorrhagia | |
AP2001002054A0 (en) | Use of biogenic estrogen sulfamates for hormone replacement therapy. | |
MY152750A (en) | Transdermal delivery system of hormones without penetration enhancers | |
YU13902A (en) | Mesoprogestins (progesterone receptor modulators) as a component of female contraceptives | |
BG101427A (en) | Competitive progesterone antagonists for regulating female fertility as required | |
WO2000074649A3 (en) | Ophthalmic histamine compositions and uses thereof | |
EP1090639A3 (en) | Pharmaceutical composition containing a progestational corticoid and a selective estrogen receptor modulator | |
AU9621598A (en) | Luteinising hormone antagonists useful for treatment of estrogen deficiencies, or as a contraceptive | |
WO2001015679A3 (en) | Mesoprogestins for the treatment and prevention of benign hormone dependent gynecological disorders | |
WO2002056903A3 (en) | Methods for treating hormone associated conditions using a combination of lhrh antagonists and specific estrogen receptor modulators | |
EA200601089A1 (en) | TRANSDERMAL DELIVERY OF HORMONES WITHOUT THE NEED TO USE AGENTS, STRENGTHENING PENETRATION | |
WO2001034126A3 (en) | Mesoprogestins (progesterone receptor modulators) as a component of compositions for hormone replacement therapy (hrt) | |
MXPA01011296A (en) | Contraceptive compositions containing indoline derivatives and progestational agents. | |
AU9028098A (en) | Combinations of endometrial sparing progestins and endometrial atrophizing progestins with estrogens, in oral contraception | |
WO1996028154A3 (en) | Use of anti-oestrogens as male contraceptives | |
IL125983A0 (en) | Pharmaceutical composition comprising factor xiiia |